Search alternatives:
point decrease » point increase (Expand Search)
mg decrease » _ decrease (Expand Search), nn decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
point decrease » point increase (Expand Search)
mg decrease » _ decrease (Expand Search), nn decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
1561
-
1562
Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.
Published 2025Subjects: -
1563
-
1564
-
1565
Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.
Published 2025Subjects: -
1566
Baseline patient characteristics across neutralizing monoclonal antibody trials.
Published 2025Subjects: -
1567
-
1568
-
1569
Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.
Published 2025Subjects: -
1570
-
1571
-
1572
Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.
Published 2025Subjects: -
1573
-
1574
Temperature-Responsive Peptide–Nucleotide Coacervates
Published 2021“…We derive a simple relation between the temperature and salt concentration at the critical point based on a mean-field model of phase separation. …”
-
1575
Temperature-Responsive Peptide–Nucleotide Coacervates
Published 2021“…We derive a simple relation between the temperature and salt concentration at the critical point based on a mean-field model of phase separation. …”
-
1576
-
1577
-
1578
-
1579
-
1580